Skip to content

MPM BIOIMPACT LLC

Follow

13F filer, CIK 1687078, BOSTON, MA

MPM BIOIMPACT LLC reported $1,347,705,655 across 37 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 49.25% of the portfolio.

Accepted , ingested 13F-HR 0001193125-26-463462

Period
2026-09-30
Reported value
$1.35B
Holdings
37
Top 10 weight
49.25%
New
10
Sold out
10

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IOVAnew+2,835,734$42M
IMCRnew+1,203,289$36.4M
VIRnew+2,809,711$31.4M
VSTMnew+3,851,604$31M
ODTXnew+1,289,091$28.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RVMDexited-492,483-$92.2M
ALMSexited-2,019,020-$56.8M
RAREexited-1,418,215-$47.4M
DNTHexited-420,002-$40.9M
CORTreduced-349,028-$40.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-463462, largest first. % of portfolio is the value over $1,299,078,595, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,648,268 shares; 2025Q1: 7,648,268 shares; 2025Q2: 7,648,268 shares; 2025Q3: 7,648,268 shares; 2025Q4: 7,648,268 shares; 2026Q1: 7,648,268 shares; 2026Q2: 9,731,341 shares; 2026Q3: 9,721,081 shares 9,721,081$149M11.49%-10,260Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,835,872 shares; 2026Q2: 4,835,872 shares; 2026Q3: 4,835,872 shares 4,835,872$94.2M7.25%0Timeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,133,365 shares; 2026Q2: 1,122,731 shares; 2026Q3: 1,088,363 shares 1,088,363$64.1M4.93%-34,368Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,079,316 shares; 2025Q1: 1,105,444 shares; 2025Q2: 1,720,741 shares; 2025Q3: 1,720,741 shares; 2025Q4: 1,655,256 shares; 2026Q1: 1,660,696 shares; 2026Q2: 1,620,780 shares; 2026Q3: 1,575,987 shares 1,575,987$64M4.93%-44,793Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,446,361 shares; 2025Q3: 1,446,361 shares; 2025Q4: 1,405,388 shares; 2026Q1: 1,408,152 shares; 2026Q2: 1,922,093 shares; 2026Q3: 3,208,146 shares 3,208,146$51.7M3.98%+1,286,053Timeline
CORTCORCEPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 985,700 shares; 2026Q2: 771,028 shares; 2026Q3: 422,000 shares 422,000$48.6M3.74%-349,028Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,268,825 shares; 2025Q1: 2,295,924 shares; 2025Q2: 2,282,680 shares; 2025Q3: 2,282,680 shares; 2025Q4: 2,232,451 shares; 2026Q1: 2,359,586 shares; 2026Q2: 2,415,672 shares; 2026Q3: 2,369,578 shares 2,369,578$42.8M3.29%-46,094Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,094,896 shares; 2025Q1: 3,428,366 shares; 2025Q2: 3,406,955 shares; 2025Q3: 3,406,955 shares; 2025Q4: 3,287,087 shares; 2026Q1: 3,298,430 shares; 2026Q2: 3,073,577 shares; 2026Q3: 2,978,906 shares 2,978,906$42.7M3.28%-94,671Timeline
IOVAIOVANCE BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,673,905 shares; 2025Q1: 2,708,582 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,835,734 shares 2,835,734$42M3.24%newTimeline
LQDALIQUIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 200,000 shares; 2025Q4: 1,400,869 shares; 2026Q1: 1,405,158 shares; 2026Q2: 1,386,174 shares; 2026Q3: 1,342,713 shares 1,342,713$40.6M3.13%-43,461Timeline
NTRANATERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 160,626 shares; 2025Q1: 157,047 shares; 2025Q2: 98,924 shares; 2025Q3: 98,924 shares; 2025Q4: 93,551 shares; 2026Q1: 93,074 shares; 2026Q2: 92,638 shares; 2026Q3: 90,585 shares 90,585$37.4M2.88%-2,053Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 135,000 shares; 2025Q4: 941,378 shares; 2026Q1: 943,803 shares; 2026Q2: 933,415 shares; 2026Q3: 909,691 shares 909,691$37M2.85%-23,724Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,203,289 shares 1,203,289$36.4M2.81%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,054,504 shares; 2025Q3: 1,054,504 shares; 2025Q4: 996,825 shares; 2026Q1: 5,213,361 shares; 2026Q2: 3,666,284 shares; 2026Q3: 3,044,659 shares 3,044,659$35.8M2.76%-621,625Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 2,953,562 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,500,000 shares; 2026Q3: 7,262,959 shares 7,262,959$35.4M2.72%+2,762,959Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 56,316 shares; 2026Q1: 107,268 shares; 2026Q2: 336,347 shares; 2026Q3: 328,379 shares 328,379$32.5M2.5%-7,968Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,809,711 shares 2,809,711$31.4M2.42%newTimeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,936,291 shares; 2026Q3: 1,956,618 shares 1,956,618$31.3M2.41%+20,327Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,851,604 shares 3,851,604$31M2.39%newTimeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,381,628 shares; 2026Q1: 1,369,231 shares; 2026Q2: 1,225,855 shares; 2026Q3: 1,201,413 shares 1,201,413$29M2.23%-24,442Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,289,091 shares 1,289,091$28.6M2.2%newTimeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 341,496 shares; 2025Q3: 341,496 shares; 2025Q4: 328,869 shares; 2026Q1: 329,750 shares; 2026Q2: 322,007 shares; 2026Q3: 352,676 shares 352,676$27.7M2.13%+30,669Timeline
PVLAPALVELLA THERAPEUTICS INC NEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 67,423 shares; 2025Q4: 205,745 shares; 2026Q1: 206,404 shares; 2026Q2: 204,027 shares; 2026Q3: 197,633 shares 197,633$27.3M2.1%-6,394Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 391,918 shares; 2026Q2: 1,042,467 shares; 2026Q3: 5,178,127 shares 5,178,127$27.2M2.1%+4,135,660Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,000 shares 300,000$25M1.92%newTimeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 1,399,514 shares; 2025Q2: 1,729,378 shares; 2025Q3: 1,729,378 shares; 2025Q4: 1,798,717 shares; 2026Q1: 1,803,945 shares; 2026Q2: 1,882,162 shares; 2026Q3: 1,821,951 shares 1,821,951$24.5M1.89%-60,211Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 685,826 shares; 2025Q1: 693,988 shares; 2025Q2: 789,698 shares; 2025Q3: 789,698 shares; 2025Q4: 770,289 shares; 2026Q1: 767,038 shares; 2026Q2: 723,314 shares; 2026Q3: 925,133 shares 925,133$24.1M1.85%+201,819Timeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 87,760 shares; 2026Q1: 88,045 shares; 2026Q2: 137,208 shares; 2026Q3: 133,387 shares 133,387$22.7M1.74%-3,821Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 771,839 shares 771,839$21.5M1.65%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,472,843 shares; 2026Q3: 4,449,671 shares 4,449,671$18.5M1.42%-23,172Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,544,354 shares; 2026Q3: 4,290,616 shares 4,290,616$18.1M1.4%+746,262Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,173,376 shares; 2026Q1: 1,176,928 shares; 2026Q2: 1,161,081 shares; 2026Q3: 1,125,216 shares 1,125,216$13.4M1.03%-35,865Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,667,661 shares; 2026Q3: 1,856,748 shares 1,856,748$13.2M1.01%+189,087Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,667,272 shares 1,667,272$11.4M0.88%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 230,147 shares; 2026Q1: 212,175 shares; 2026Q2: 202,114 shares; 2026Q3: 195,669 shares 195,669$9.75M0.75%-6,445Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 254,374 shares 254,374$9.02M0.69%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
CORTCORCEPT THERAPEUTICS INC COMput422,000$48.6Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RVMDREVOLUTION MEDICINES INC492,483$92.2Mshares
ALMSALUMIS INC2,019,020$56.8Mshares
RAREULTRAGENYX PHARMACEUTICAL IN1,418,215$47.4Mshares
DNTHDIANTHUS THERAPEUTICS INC420,002$40.9Mshares
MLTXMOONLAKE IMMUNOTHERAPEUTICS1,606,967$31.3Mshares
SNDXSYNDAX PHARMACEUTICALS INC1,333,523$29.2Mshares
FBRXFORTE BIOSCIENCES INC987,448$21Mshares
TRDAENTRADA THERAPEUTICS INC1,253,053$9.22Mshares
CNTXCONTEXT THERAPEUTICS INC1,299,046$720Kshares
HOWLWEREWOLF THERAPEUTICS INC80,142$28.9Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-463462 base2026-11-16